2777P Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer

J. Bar; A. Dowlati; L.A. Byers; B.C. Cho; A J Cooper; J-Y. Han; D. Morgensztern; M. Furqan; Y-C. Kim; K.P. Papadopoulos; R.R. Robinson; P. Hingorani; F.J. Kohlhapp; M.A. Pysz; D. Clausznitzer; C. Zhou; C. Ferlini; A.C. Chiang

doi:10.1016/j.annonc.2025.08.3388

$2777P Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer$

Abstract

Peer reviewed

2777P Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer

J. Bar, A. Dowlati, L.A. Byers, B.C. Cho, A J Cooper, J-Y. Han, D. Morgensztern, M. Furqan, Y-C. Kim, K.P. Papadopoulos, …

Annals of oncology, Vol.36(Suppl 2), p.S1477

09/2025

DOI: 10.1016/j.annonc.2025.08.3388

View Online

Abstract

Background First-line (1L) standard of care (SOC) for extensive-stage small cell lung cancer (SCLC) includes platinum chemotherapy + etoposide (PE), with a PD-L1 inhibitor. ABBV-706 is an antibody-drug conjugate composed of a potent topoisomerase 1 inhibitor attached via a stable linker to a SEZ6-directed monoclonal antibody. Here, we present data on the efficacy of ABBV-706 in patients (pts) with platinum-refractory/resistant SCLC. Methods The antitumor effects of ABBV-706 and PE were tested in SCLC pt-derived xenografts (PDX); a model integrating exposure/efficacy in PDX was generated. To assess the anticancer effect of ABBV-706 monotherapy vs PE, a posthoc analysis was done on data from pts with 2L+ SCLC enrolled in part 2a of study NCT05599984. Progression-free survival (PFS), overall response rate (ORR), and duration of response (DOR) were evaluated. All pts enrolled in NCT05599984 received 1L PE; PFS during 1L SOC (PFS-L1) and PFS with ABBV-706 as subsequent line of treatment (PFS-706) were analyzed in the same pts by paired Kaplan-Meier analysis. Results In PDX, ABBV-706 is superior to PE in terms of antitumor effects; at equivalent human exposure of 1.8 and 2.5 mg/kg, tumor cell killing was 424% and 595% vs PE (100%), respectively. Data from 80 pts with 2L+ SCLC (median follow-up ∼8 mo) were analyzed in terms of efficacy outcomes, as shown in the table. PFS-706 was comparable with PFS-L1 in general, and longer than PFS-L1 for pts with PE-resistant (CTFI <90 days) or PE-refractory (CTFI <30 days) SCLC. Cross-trial comparison showed that ABBV-706 had improved efficacy (ORR, DOR, and PFS) compared with approved 2L agents lurbinectedin and topotecan. Conclusions Despite being used in a later line, ABBV-706 exhibited comparable PFS to 1L SCLC SOC, and longer PFS in PE-resistant or PE-refractory SCLC. Given the antitumor effect observed in PDX models and improved outcomes in PE-resistant pts from NCT05599984, ABBV-706 has the potential to replace 1L SOC in SCLC.

Details

Title: Subtitle: 2777P Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer
Creators: J. Bar
A. Dowlati
L.A. Byers
B.C. Cho
A J Cooper - Memorial Sloan Kettering Cancer Center
J-Y. Han
D. Morgensztern
M. Furqan
Y-C. Kim
K.P. Papadopoulos
R.R. Robinson
P. Hingorani
F.J. Kohlhapp
M.A. Pysz
D. Clausznitzer
C. Zhou
C. Ferlini
A.C. Chiang
Resource Type: Abstract
Publication Details: Annals of oncology, Vol.36(Suppl 2), p.S1477
DOI: 10.1016/j.annonc.2025.08.3388
ISSN: 0923-7534
eISSN: 1569-8041
Publisher: Elsevier
Grant note: AbbVie
Medical writing support was provided by Judith Land, PhD, CMPP, of Aptitude Health, The Hague, the Netherlands, and funded by AbbVie.
Language: English
Date published: 09/2025
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9985027464802771

Metrics

17 Record Views